ACADIA Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
ACADIA Pharmaceuticals Stock Forecast and Price Target
ACADIA Pharmaceuticals's stock price reaches the average target of $30.00 by 2025 as expected recently by six notable experts, there would be a potential upside of approximately 79.53% from the last closing price in April, 2024. This possible increase is based on a high estimate of $39.00 and a low estimate of $13.00. If you're looking for ACADIA Pharmaceuticals (ACAD) stock information, you might also want to check out Amgen (NasdaqGS:AMGN).
79.53% Upside
ACADIA Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, ACADIA Pharmaceuticals's Price has grown by 100.00%, rising from $0.00 to $0.00. For next year, analysts predict Fair Value of $17.98, which would mean an increase of 100.00%. Over the next seven years, experts predict that ACADIA Pharmaceuticals's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$159.62 | Buy/Sell | $178.42 | 18.41% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$269.98 | Buy/Sell | $303.65 | 17.51% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.42 | Buy/Sell | $87.82 | 22.29% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$208.90 | Buy/Sell | $299.62 | 38.10% |
ACADIA Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last three years, ACADIA Pharmaceuticals's Revenue has grown by 64.44%, rising from $441.76M to $726.44M. For next year, analysts predict Revenue of $955.29M, which would mean an increase of 31.50%. Over the next seven years, experts predict that ACADIA Pharmaceuticals's Revenue will grow at a rate of 160.19%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$80.91 | Buy/Sell | $111.56 | 35.95% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$51.68 | Buy/Sell | $77.05 | 49.38% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$74.31 | Buy/Sell | $34.00 | 54.76% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$93.00 | Buy/Sell | $85.71 | 7.53% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.28 | Buy/Sell | $17.90 | 94.55% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$11.64 | Buy/Sell | $20.42 | 119.07% |
ACADIA Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, ACADIA Pharmaceuticals's EBITDA has decreased by 70.47%, from $-230.85M to $-68.16M. For the next year, 5 analysts project ACADIA Pharmaceuticals's EBITDA to drop by 275.56%, reaching $119.66M. By 2030, professionals believe that ACADIA Pharmaceuticals's EBITDA will decrease by 2061.94%, reaching $1.34B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$22.12 | Buy/Sell | $52.00 | 139.60% |
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$36.30 | Buy/Sell | $63.29 | 112.12% |
ACADIA Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last three years, ACADIA Pharmaceuticals's EBIT has fallen from $-233.79M to $-73.38M – a 68.61% decrease. According to 16 prominent analysts, ACADIA Pharmaceuticals's EBIT will fall by 308.24% in the next year, reaching $152.81M. By 2030, professionals believe that ACADIA Pharmaceuticals's EBIT will decrease by 1362.09%, reaching $926.12M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VCEL Stock Forecast | Vericel | Buy |
8
|
$46.05 | Buy/Sell | $42.58 | 19.44% |
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$6.42 | Buy/Sell | $9.94 | 118.07% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.21 | Buy/Sell | $25.00 | 118.55% |
ACADIA Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, ACADIA Pharmaceuticals's EPS has grown by 100.00%, rising from $-1.79 to $0.00. For next year, analysts predict EPS of $0.91, which would mean an increase of 100.00%. Over the next seven years, experts predict that ACADIA Pharmaceuticals's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$31.49 | Buy/Sell | $40.00 | 38.14% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.55 | Buy/Sell | $6.00 | 22.14% |
| BCRX Stock Forecast | BioCryst Pharmaceuticals | Outperform |
7
|
$4.16 | Buy/Sell | $14.09 | 152.40% |
Site Navigation
.jpg)